Menu
“Prometheus” basic science key note lecture:
Targeting the ubiquitin proteasome system to fight muscle atrophy: update 2022
Volker Adams, Germany
“Hippocrates” clinical science key note lecture:
From sarcopenia to frailty
John Morley, USA
JCSM & SCWD lecture
Stephan von Haehling, Germany
Chair: Paola Costelli, Italy
MOTS-c: a new player in aging-related loss of muscle mass and function
Changhan Lee, USA
Metabolic and molecular consequences of sarcopenia in alcoholic liver disease
Srinivasan Dasarathy, USA
Bone and muscle crosstalk: Biological and clinical implications
Gustavo Duque, Australia
Results of the SPRINTT trial
Francesco Landi, Italy
Chairs: Stephan Herzig, Germany, & Mauricio Berriel Diaz, Germany
Immune-sympathetic neuron communication guides adipose tissue browning in cancer-associated cachexia
Martina Schweiger, Austria
Angiocrine signals promote adipose tissue wasting in cancer cachexia
Andreas Fischer, Germany
Brown adipose tissue activation is not related to hypermetabolism in emphysematous COPD patients
Annemie Schols, The Netherlands
MRI-determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia
Dimitrios Karampinos, Germany
Chairs: John Morley, USA, & Andrew Coats, Australia
Appetite is key in geriatric syndromes: a pre-release of SCWD International Guidelines on Anorexia of Aging
Ivan Aprahamian, Brasil
Development of the cachexia consensus in Asia
Hidenori Arai, Japan
Recent guidelines on cancer cachexia: ESPEN, ESMO and ASCO
Alessandro Laviano, Italy
Appetite is key in geriatric syndromes: a pre-release of SCWD International guidelines on anorexia of aging
Ivan Aprahamian, Brazil
Development of the cachexia consensus in Asia
Hidenori Arai, Japan
Recent guidelines on cancer cachexia: ESPEN, ESMO and ASCO
Alessandro Laviano, Italy
Chair: Fabio Penna, Italy
Doxorubicin-induced skeletal muscle atrophy, underlying molecular pathways and potential protective effects of exercise: Evidence from pre-clinical and clinical data
Anouk Hiensch, The Netherlands
Exercise and Nutrition-based Rehabilitation programme (EneRgy) in people with cancer
Barry Laird, UK
Resistance training during chemotherapy for non-metastatic colon cancer: The FORCE study: Effects on body composition and physical function
Bette Caan, USA
Effects of exercise in patients after curative treatment for esophageal cancer: body composition and adequacy of energy and protein intake (the PERFECT study)
Anne May, The Netherlands
10 abstracts – 5 min
Chair: Gustavo Nader, USA
Activation of Akt-mTORC1 signaling reverts cancer-dependent muscle wasting
Bert Blaauw, Italy
New insights into the role of GCN2-eIF2alpha signaling in the regulation of autophagy
Anne-Catherine Maurin, France
Interventions for improving mitochondrial function to counteract cancer and chemotherapy-induced cachexia
Fabio Penna, Italy
Fighting muscle loss: lessons from hibernation in brown bear
Etienne Lefai, France
Chair: Stephan von Haehling, Germany
Artificial Intelligence approaches to improve speed, dimensionality and entry into clinical workflows
Faisal Beg, Canada
Surrogate markers of muscle mass and quality
Cristina Gonzalez, Brazil
A mechanistic perspective of specialized nutrition for muscle health
Philip Atherton, UK
Rapid Fire Abstracts Session 2
10 abstracts – 5 min
Chair: Annemie Schols, The Netherlands
Mechanisms of ammonia induced sarcopenia – a common mediator in multiple diseases
Srinivasan Dasarathy, USA
Amino acid perturbations in hyperammonemia
Milan Holecek, Czech Republic
Multiomics based approaches to identify novel cellular and tissue responses
Nicole Welch, USA
The significance of myosteatosis in surgical cancer patients
Steven Olde Damink, The Netherlands
Chair: Wolfram Doehner, Germany
What determines/Which parameters determine optimal protein metabolism in the old?
Dominique Dardevet, France
Manipulating the microbiome to counteract frailty
Patrizia Brigidi, Italy
Nutrition and anorexia of ageing
Reshma Merchant, Singapore
Chairs: Andrea Bonetto, USA, & Andrew Coats, Australia
Hepatic and intestinal disturbances as targets to counteract cancer cachexia
Laure Bindels, Belgium
A cachexia score based on liver alterations predicts prognosis of gastrointestinal cancer patients
Achim Krüger, Germany
Inflammation and impairment of hepatic metabolism and function in cachectic cancer patients
Marilia Seelaender, Brazil
Liver control of systemic energy metabolism in cancer cachexia
Sören Fisker Schmidt, Denmark
Muscle stem cells in age and disease
Julia von Maltzahn, Germany
Neurofibromatosis type 1 associated myopathy is due to metabolic reprogramming of muscle stem cells in a mouse model
Sigmar Stricker, Germany
Fibro-adipogenic progenitors coordinate muscle regeneration
Georgios Kotsaris, Germany
Muscle stem cells drive post-sepsis skeletal muscle recovery and regeneration
Jason Doles, USA
Chairs: Frank Misselwitz, Germany, & Gustavo Nader, USA
Abnormal liver-bone-muscle axis in cancer cachexia
Andrea Bonetto, USA
Impact of exercise and chemotherapy on the respiratory neuromuscular system
Ashley Smuder, USA
Cancer-induced muscle and bone deficits
Hanna Taipaleenmäki, Germany
Cardiac cachexia
Markus Anker, Germany
10 abstracts – 5 min
Chairs: Jochen Springer, Germany, Marilia Seelaender, Brazil, & Maria Rohm, Germany
Sex-dependent response of adipose tissue and lipid metabolism in cancer cachexia
Vera Mazurak, Canada
Tumor microenvironment evolution and its relevance to cachexia
Mariam Jamal-Hanjani, UK
Sex variation in cachexia
Silvia Busquets, Spain
Anabolic deficits in muscle wasting: paradigm lost or blind spot?
Gustavo Nader, USA
Chair: Gustavo Duque, Australia
Integrated evaluation of body composition in the oncology setting: paradigm change
David da Silva Dias, Portugal
Nutrition options in 2022: What is on the market?
Paula Ravasco, Portugal
Nutrition in ambulatory cytotoxic treatment: New data on the role of the clinical pharmacist
Leila Costa, Portugal
Head and neck cancer and cachexia – a high risk cancer and higher risk treatments
Maartje van Beers, The Netherlands
Circulating GDF15 and its relationship with cachexia in non-small cell lung cancer
Mariam Jamal-Hanjani, UK
GDF-15 is a key regulator of cancer cachexia and beyond
Bei Zhang, USA
Questions & Answers
Supported by an educational grant from Pfizer
Chairs: Denis Guttridge, USA, Martina Schweiger, Austria, & Stephan von Haehling, Germany
Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia
Tobias Janowitz, USA
Tumor-derived cachexia mediators and biomarkers
Mauricio Berriel Diaz, Germany
Tumor-derived extracellular vesicles
Paola Costelli, Italy
KLF10: a novel mediator of cancer-associated skeletal muscle wasting
Jason Doles, USA
Exercise and tumor control: expanding the field of exercise oncology to cancer progression and cachexia
Lee Jones, USA
Cardiac wasting in cancer
Alessia Lena, Germany
A review of the evidence for multi-modal interventions in cachexia management
Joanne Reid, UK
ACTAs for cancer cachexia
Andrew Coats, Australia
MyomiRNA, systemic and local inflammation and muscle wasting
Maurizio Muscaritoli, Italy
The transcriptional repressor FoxP1 in cancer-induced skeletal muscle wasting and weakness
Sarah Judge, USA
Beyond good and evil: Discovering novel anabolic targets to overcome cancer related-muscle wasting
Marcelo Pereira, UK
Skeletal muscle mitochondrial dysfunction and lipid accumulation in breast cancer
Emidio Pistilli, USA
Chairs: Teresa Zimmers, USA, & Andrew Coats, Australia
Definition of cancer cachexia and measuring muscle mass in clinical trials
Vickie Baracos, Canada
Endpoints for cancer cachexia clinical trials
Stefan Anker, Germany
Use of biomarkers to assess treatment effect in cancer cachexia
Jose Garcia, USA
Regulatory perspective on Cancer Cachexia Trials
Giuseppe Rosano, UK
Chairs: Marco Sandri, Italy, Jason Doles, USA, & Denis Guttridge, USA
T cells and cachexia
Laura Antonio-Herrera, Austria
NMJ defects and stem cell defects in wasting muscle
Joe Chakkalakal, USA
Macrophages and muscle regeneration
Emanuele Berardi, Belgium
Endothelial dysfunction in cachexia
Young-Mee Kim, USA
Chairs: Mauricio Berriel Diaz, Germany, & Puneeth Iyengar, USA
Host factors: sexual dimorphism in murine models of cancer cachexia
Nicholas Greene, USA
Host factors: aging and host genotype in cancer cachexia
Maria Rohm, Germany
Tumor factors: tumor molecular and cellular heterogeneity mediates cancer cachexia phenotype
Teresa Zimmers, USA
In vivo screening reveals lung cancer tumor-specific mediators of cancer cachexia in mice
Rodney Infante, USA
Impact of protein intake on CKD cachexia and sarcopenia
Kam Kalantar-Zadeh, USA
Physical activity and nutrition in CKD
Angela Wang, Hong Kong
Inflammation and adipose tissue browning in CKD cachexia
Robert Mak, USA
Activin signaling and GDF-15 in CKD cachexia
Connie Rhee, USA
Chairs: Mauricio Muscaritoli, Italy, Annemie Schols, The Netherlands, & Mitja Lainscak, Slovenia
The role of adipose tissue in Covid-19 cytokine storm: learning from cachexia
Marilia Seelaender, Brazil
Nutrition: a matter of life or death
Alessandro Laviano, Italy
Body composition and muscle quality in Covid-19 patients
Martine Sealy, The Netherlands
Frailty and rehabilitation in Covid-19 patients
Francesco Landi, Italy
Chair: Joanne Reid, UK
Evolution and outcomes from a multi-disciplinary cachexia clinic
Peter Martin, Australia
Clarifying the role of palliative rehabilitation in cachexia management
Cathy Payne, Belgium
The importance of exercise and nutrition in an integrated response to cachexia management
Adrian Slee, UK
Patient experience of a multi-professional cachexia clinic
Vanessa Vaughan, Australia
Chair: Teresa Zimmers, USA
MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer
Andrew R. Judge, USA
Activation of p38β MAPK in skeletal muscle correlates with weight loss in cancer patients
Yi-Ping Li, USA
Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients
Alessio Molfino, Italy
Adipose depot gene expression and intelectin-1 in the metabolic response to cancer and cachexia
Richard J. E. Skipworth, UK
Chair: Maurizio Muscaritoli, Italy
GDF15 neutralization as a transformative therapeutic approach
Bei Zhang, Pfizer, USA
Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15
Danna Breen, USA
MC4R antagonism for appetite and body weight regulation – from human genetics to aged rat model
Zhidan Wu, USA
Copyright © 2009 – 2022 Society on Sarcopenia, Cachexia and Wasting Disorders. All Rights Reserved. Data Privacy